← All trials
NCT04887025
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2022
- Primary completion
- Mar 15, 2023
- Completion date
- Mar 15, 2025
- First posted
- May 14, 2021
- Last posted
- Sep 1, 2021
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.